Verixa β€” Demo Scenarios & Acceptance Criteria (6 + 1)

πŸ”„ Patent-filing date realignment Β· 18 Jun β†’ 26 Jun β†’ 03 Jul 2026
Patent FD target shifted from 15 Jun 2026 to 26 Jun 2026 03 Jul 2026. All FD+N statutory and decision dates shift accordingly: Β§39 clock starts 26 Jun 03 Jul Β· complete specifications due 26 Jun 2027 03 Jul 2027 (Β§9(1)) Β· PCT decision 26 Dec 2026 03 Jan 2027 Β· US/EU national-phase entry 26 Dec 2028 03 Jan 2029 Β· Request for Examination 26 Jan 2029 03 Feb 2029. Marketing public-disclosure window also shifts: founder 1-to-1 outbound to known DP targets continues pre-FD under NDA; public marketing (newsletter Β· pillar pages Β· founder LinkedIn cadence Β· PR note Β· webinar invites) unlocks Mon 29 Jun 2026 Tue 07 Jul 2026 (W5) post-FD. Engineering W1-W14 pilot timeline holds: demo lock Fri 26 Jun Β· Verified Go-Live Decision Tue 01 Sep.
β˜… Master β†— Investment β†— Patent β†— Development β†— Pilot Launch β†— GTM β†— Product Roadmap β†— QMS / Validationβ†— Security & Trustβ†— Legal & Entity β†— Dataset Tracker
Demo tenant: Acme Sterile Pharma (fictional) β€” Injectable Line 3 Β· synthetic data only Β· demo-ready 26 June 2026 Β· source reconciled @ cc6e6157 Β· HTML built from Verixa_Demo_Scenario_and_EndUser_AcceptanceCriteria_6plus1.md (2026-06-10)
πŸ”¬ Code-audit reconciliation (2026-06-13, HEAD 6dfca132): the 5 controls demoted to TARGET in this doc were reconciled at cc6e6157. A later code audit found several advanced: DV-11 / IR-6 / DC-11 addressed; RC-9 largely (creatorβ‰ approver & creatorβ‰ closer enforced); CA-13 (CAPA item-level reviewer SoD) remains the one true open gap. Re-confirm against the exact demo build before flipping any status. See the Code Audit + Development Tracker.
6+1
workflows (DocΒ·DevΒ·RCAΒ·CAPAΒ·EvidenceΒ·Inspection +MIRA)
3
demo users (SoD enforced)
69
acceptance criteria (Part B) + 8 admin (AG)
5β†’1
controls demoted @cc6e6157 Β· 1 still open (CA-13) post-audit
'; dl("Verixa_Status_"+FILE.replace(/\.html?$/,"")+"_"+new Date().toISOString().slice(0,10)+".doc", new Blob(['ο»Ώ'+h],{type:"application/msword"})); } function exportText(){ var s=snapshot(); var sec=""; var L=["VERIXA β€” STATUS SNAPSHOT","Source: "+TITLE,"Generated: "+stamp(), "Completed: "+s.counts["Completed"]+" | In Progress: "+s.counts["In Progress"]+" | Not Started: "+s.counts["Not Started"]+" | Unset: "+s.counts["β€”"],""]; s.rows.forEach(function(r){ if(r.section!==sec){sec=r.section;L.push("");L.push("== "+sec+" ==");} L.push(" ["+r.status+"] "+r.id+(r.title?" β€” "+r.title:"")); }); dl("Verixa_Status_"+FILE.replace(/\.html?$/,"")+"_"+new Date().toISOString().slice(0,10)+".txt", new Blob([L.join("\n")],{type:"text/plain;charset=utf-8"})); } function buttons(){ if(document.getElementById("vxstatus-bar")) return; var bar=document.createElement("div"); bar.id="vxstatus-bar"; bar.style.cssText="position:fixed;right:16px;bottom:16px;z-index:9999;display:flex;gap:8px"; function mk(label,fn){var b=document.createElement("button");b.textContent=label; b.style.cssText="background:#FFE388;color:#2a2200;border:none;border-radius:18px;padding:9px 14px;font-size:12.5px;font-weight:700;cursor:pointer;box-shadow:0 2px 10px rgba(0,0,0,.4)"; b.addEventListener("click",fn);return b;} bar.appendChild(mk("– Word",exportWord)); bar.appendChild(mk("– Text",exportText)); document.body.appendChild(bar); } function run(){enhance();buttons();} if(document.readyState==="loading"){document.addEventListener("DOMContentLoaded",run);}else{run();} var obs=new MutationObserver(function(muts){ for(var i=0;i